Tagamet HB 200 Suspension Safety Data In Children Requested By FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA has asked SmithKline Beecham to conduct a "pharmacodynamic/safety study in pediatric subjects less than 12 years of age, if such data are not available," for Tagamet HB 200 suspension. The suspension form of the H2 antagonist cimetidine was approved July 9. SmithKline submitted NDA 20-951 Dec. 29, 1997.
You may also be interested in...
Tagamet HB 200 Liquid
National TV advertising breaks June 5 for first OTC liquid H2 antagonist. SmithKline Beecham's Tagamet HB extension launched in April (1"The Tan Sheet" May 15, p. 4). FSIs with a $2-off coupon for any size liquid and a $1 coupon for 12-count tablets will continue to be distributed throughout the year, accompanied by in-store promotions and $5 rebate coupons available with product on retail shelves, SB says. Product employs an accordion-style label in order to fit all necessary instructions and warnings (2"The Tan Sheet" July 19, 1999, p. 5)
Aquafresh Gum, Lozenges Carry "For Oral Care - Anytime, Anywhere" Tagline
SmithKline Beecham is moving its Aquafresh brand beyond the traditional dentrifice category into what appears to be the confectionary market.
Pepcid AC Chewables Emphasize "Just One" Tablet Per Dose
Directions for use of J&J/Merck's newly approved Pepcid AC Chewable famotidine specify "just one" tablet should be swallowed with water, according to labeling approved by FDA for the line extension. The product was green lighted by the agency Sept. 24 ("The Tan Sheet" Sept. 28, p. 18).